Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New

Micro-Abstract We reviewed our institutional experience with the adjuvant regimen of oral cyclophosphamide, with weekly intravenous methotrexate and 5-fluorouracil in 248 women to evaluate effectiveness and tolerability in a well-characterized, modern breast cancer cohort. At a median follow-up of 6...

Full description

Saved in:
Bibliographic Details
Published inClinical breast cancer Vol. 15; no. 5; pp. e277 - e285
Main Authors Cho, Eunpi, Schwemm, Ann K, Rubinstein, Lena M, Stevenson, Philip A, Gooley, Ted A, Ellis, Georgiana K, Specht, Jennifer M, Livingston, Robert B, Linden, Hannah M, Gadi, Vijayakrishna K
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.10.2015
Subjects
Adjuvant chemotherapy
Adult
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cohort Studies
Cyclophosphamide
Cyclophosphamide - adverse effects
Cyclophosphamide - therapeutic use
Disease-Free Survival
Female
Fluorouracil
Fluorouracil - adverse effects
Fluorouracil - therapeutic use
Follow-Up Studies
Hematology, Oncology and Palliative Medicine
Hormone-receptor positive
Humans
Methotrexate
Methotrexate - adverse effects
Methotrexate - therapeutic use
Middle Aged
Neoplasm Staging
Obstetrics and Gynecology
Adjuvant chemotherapy
Cyclophosphamide
Hormone-receptor positive
Methotrexate
Fluorouracil
Online AccessGet full text

Cover

More Information
Summary:Micro-Abstract We reviewed our institutional experience with the adjuvant regimen of oral cyclophosphamide, with weekly intravenous methotrexate and 5-fluorouracil in 248 women to evaluate effectiveness and tolerability in a well-characterized, modern breast cancer cohort. At a median follow-up of 67 months, the recurrence rate was only 6%.
ISSN:1526-8209
1938-0666
DOI:10.1016/j.clbc.2015.04.002